ClinicalTrials.gg

Program

HRS-9231

A development code. Also written as “HRS-9231 Injection”.

In Jiangsu HengRui Medicine's pipeline, Gd Contrast agent. Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Nov 18, 20255 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine51 open or runningphase 3since Nov 18, 2025Oct 23, 2024none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-9231, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2024First study: phase 1 study in Contrast-Enhanced Magnetic Resonance Imaging DetectionFirst studyNCT06657560 · 41 enrolled · China
  2. Dec 9, 2024Phase 2 study in For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) LesionsNCT06731829 · 78 planned · China
  3. Aug 8, 2025Phase 1 study in Healthy VolunteersNCT07123376 · 40 enrolled · China
  4. Nov 18, 20252 phase 3 studiesPhase 3 reachedNCT07275814, NCT07275723

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Gd Contrast agent”the company's pipeline, read by Claude · source

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07275814For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions · China3CompletedJun 17, 2026250
NCT07275723For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) · China3CompletedApr 18, 2026309
NCT07123376Healthy Volunteers · China1CompletedOct 6, 202440
NCT06731829For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions · China2Not yet recruitingApr 202578
NCT06657560Contrast-Enhanced Magnetic Resonance Imaging Detection · China1CompletedJul 3, 202541

How it is read

Names in the registry

  • “HRS-9231”, 3 entries
  • “HRS-9231 Injection”, 2 entries

Codes read as this program: HRS9231.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.